### Corona Remedies IPO: A Significant Event in the Pharma Sector The Corona Remedies IPO, which opened for subscription on December 8, 2025, is poised to raise approximately ₹655.37 crores. The price band for the shares is set between ₹1,008 and ₹1,062, with a retail quota of 35%, Qualified Institutional Buyers (QIB) at 50%, and Non-Institutional Investors (NII) at 15% [https://ipowatch.in/corona-remedies-ipo-subscription-status]. This IPO is particularly noteworthy due to the company's strong revenue growth and healthy profit margins, making it a key listing in the pharmaceutical sector [https://www.angelone.in/news/ipos/corona-remedies-ipo-opens-on-monday-dec-8-key-details-price-band-and-financial-performance]. ### Breakdown of the IPO Structure and Subscription Status 1. **IPO Details**: - **Opening Date**: December 8, 2025 - **Closing Date**: December 10, 2025 - **Total Amount to be Raised**: ₹655.37 crores - **Price Band**: ₹1,008 to ₹1,062 per share - **Equity Share Face Value**: ₹10 [https://newzly.co.in/business-finance/corona-remedies-ipo-to-open-on-december-8-price-band-set-at-₹1008-₹1062]. 2. **Subscription Quotas**: - **Retail Investors**: 35% - **Qualified Institutional Buyers (QIB)**: 50% - **Non-Institutional Investors (NII)**: 15% [https://ipowatch.in/corona-remedies-ipo-subscription-status]. 3. **Investor Response**: - As of Day 1, the subscription status is actively monitored, with live updates available for investors to gauge interest and potential listing gains [https://univest.in/blogs/corona-remedies-ipo-subscription-day-1]. ### Supporting Evidence and Data - **Financial Performance**: The company has demonstrated robust revenue growth, which is a critical factor for investor confidence in the IPO [https://www.angelone.in/news/ipos/corona-remedies-ipo-opens-on-monday-dec-8-key-details-price-band-and-financial-performance]. - **Market Sentiment**: Initial responses from investors indicate a positive outlook, with many looking forward to the potential listing gains based on the company's financial health [https://groww.in/blog/corona-remedies-ipo-day-1]. ### Conclusion: Key Takeaways from the Corona Remedies IPO 1. **IPO Launch**: The Corona Remedies IPO opened on December 8, 2025, with a target of raising ₹655.37 crores. 2. **Subscription Structure**: The IPO features a well-defined subscription structure, with significant allocations for retail and institutional investors. 3. **Investor Interest**: Early indications suggest strong investor interest, reflecting confidence in the company's financial performance and market position. In summary, the Corona Remedies IPO represents a significant opportunity for investors in the pharmaceutical sector, with its strong financial metrics and favorable market conditions potentially leading to substantial listing gains [https://groww.in/blog/corona-remedies-ipo-to-open-on-december-8].